Dipyrone use during pregnancy and adverse perinatal events
To evaluate the risk of adverse perinatal events among newborns exposed to dipyrone during gestation.
Design and Setting
The present study is a secondary analysis of Brazilian study of gestational diabetes (EBDG), a cohort of women attended at healthcare units of the Brazilian national health system (SUS) located in six Brazilian state capitals, between February 1991 and June 1995.
A total number of 5,564 women aged 20 years and over who were between their 21st and 28th week of pregnancy were followed up.
A structured questionnaire was used to obtain data on the pregnant women, their pregnancies, and their use of medications. Other data and the outcomes congenital abnormalities, intrauterine death, preterm birth, or low birth weight were obtained from the medical records. To estimate the odds ratios after adjustment for the potential confounding factors, logistic regression modeling was developed.
Main outcome measures
Congenital abnormalities, intrauterine death, preterm birth, and low birth weight.
Dipyrone use was reported by 555 pregnant women (11.5%). Their exposure to this medication did not present any association with the outcomes of congenital abnormalities (OR 1.11; 95% CI, 0.58–2.10), intrauterine death (OR 0.69; 95% CI, 0.33–1.43), preterm birth (OR 0.94; 95% CI, 0.73–1.20), or low birth weight (OR 0.88; 95% CI, 0.64–1.22), in the crude analysis. This absence of associations was maintained after performing logistic regression analysis.
The data suggest that the exposure to dipyrone during pregnancy does not increase the risk of congenital abnormalities and other adverse events as outcomes from pregnancy.
KeywordsDipyrone Congenital abnormalities Intrauterine death Preterm birth Low birth weight
- 3.International panel on the evaluation of safety of dipyrone use (on line) (2007). Available on 20 April 2007 at http://www.anvisa.gov.br/divulga/informes/relatoriodipirona2.pdf
- 8.Catalán JL, Santonja J, Martinez L, Jiménez NV (1994) Oligoamnios asociado al uso de dipirona. Med Clin (Barc) 105:541–543Google Scholar
- 14.Brazil. Ministry of Health. Secretary of ScienceTechnology Strategic Products. Department of Pharmaceutical Assistance Strategic Products (2007) National list of essential medicines—RENAME, 4th edn. Ministry of Health Press, Brasília, p 285Google Scholar